镭-223治疗转移性去势抵抗性前列腺癌骨转移相关研究进展

Radium-223 in the Treatment of Patients with Metastatic Castrate-Resistant Prostate Cancer and Bone Metastases

近年来,转移性去势抵抗性前列腺癌(mCRPC)的发病率越来越高,而mCRPC最常见的转移部位为骨,由此造成的以病理性骨折和脊髓压迫为主的骨相关事件(SREs)对患者的生存时间和生活质量造成严重威胁。目前部分mCRPC标准治疗方案,如双膦酸盐、β射线放射治疗(如89Sr)等,虽然能够延缓SREs的发生,但总生存时间(OS)和无进展生存时间(PFS)无明显改善。而镭-223(radium-223)不仅可缓解mCRPC患者的骨痛症状,延长其生存时间,还可将药物毒性降至最低。了解前列腺癌骨转移机制和镭-223的作用原理、安全性、临床应用等,对mCRPC骨转移的治疗具有重要意义。

In recent years,the incidence of metastatic castrate-resistant prostate cancer(mCRPC)has been increasing.Since bone is its most common metastasis site,the resulting skeletal-related events(SREs),mainly pathological fractures and spinal cord compression,pose a serious threat to the survival time and quality of life of patients.Current standard therapies such as bisphosphonates and beta radiation therapy(like 89Sr)could delay the onset of SREs,but they could not prolong the overall survival time(OS)and progression-free survival time(PFS).The emergence of radium-223 could not only alleviate bone pain,prolong the survival time of patients,but also could minimize drug toxicity.It is of great significance to understand the mechanism of prostate cancer bone metastases and the principle,safety,clinical application of radium-223 in the treatment of patients with metastatic bone mCRPC.